◆英語タイトル:Minoryx Therapeutics sl - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11229
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Minoryx Therapeutics sl (Minoryx) is a clinical stage biotechnology company that develops treatments for life threatening rare diseases. The company offers discovery, preclinical research, development and clinical trial programs. It develops ALD-MIN, morquio B and PCT drugs used for lysosomal storage disorders and inherited peroxisomal neurodegenerative disorders. Minoryx also develops new class of compounds and non-competitive pharmacological chaperones that are identified through its innovative proprietary platform. The company offers pharmacological chaperone technology that provides class of small molecule drugs that stabilize unstable proteins. It provides solutions for treatment of genetic diseases severely affecting the central nervous system. The company operates in Mataro and Barcelona, Spain. Minoryx is headquartered in Mataro, Spain.
Minoryx Therapeutics sl – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Minoryx Therapeutics Raises USD25 Million in Series B Financing 11
Minoryx Therapeutics Raises USD22 Million in Series A Financing Round 13
Minoryx Therapeutics Raises Additional USD0.8 Million in Seed Financing 15
Minoryx Therapeutics Raises US$2 Million In First Round Of Financing 16
Licensing Agreements 17
Minoryx Therapeutics Enters Into Licensing Agreement with Universitat de Barcelona and Institut de Investigacio Biomedica de Bellvitge 17
Minoryx Therapeutics Enters into Licensing Agreement with Bellvittge Biomedical 18
University of Barcelona And ICREA Enter Into Licensing Agreement With Minoryx 19
Equity Offering 20
Gain Therapeutics Spin Out from Minoryx Therapeutics 20
Minoryx Therapeutics sl – Key Competitors 21
Minoryx Therapeutics sl – Key Employees 22
Minoryx Therapeutics sl – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Corporate Communications 24
Feb 08, 2017: Dr Claude Nicaise joins Minoryx Therapeutics as independent board member 24
Jan 18, 2017: Minoryx Therapeutics further strengthens its Scientific Advisory Board (SAB) 25
Product News 27
09/05/2018: Minoryx Therapeutics announces dosing of first US patient in phase 2/3 clinical study of MIN-102 (ADVANCE) 27
01/18/2017: Minoryx Therapeutics further strengthens its Scientific Advisory Board (SAB) 28
01/04/2018: Minoryx Therapeutics Announces The Dosing Of First Patient In Advance, A Phase 2/3 Clinical Study Of Min-102 In Patients With Adrenomyeloneuropathy (Amn) 30
Product Approvals 32
Feb 22, 2017: Minoryx Therapeutics receives Orphan Drug Designation from the US FDA for its lead candidate MIN-102 32
Clinical Trials 33
Mar 21, 2017: Minoryx Therapeutics successfully completes phase 1 clinical trial for lead candidate MIN-102 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34
List of Tables
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Key Facts 2
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Minoryx Therapeutics sl, Deals By Therapy Area, 2012 to YTD 2018 8
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Minoryx Therapeutics Raises USD25 Million in Series B Financing 11
Minoryx Therapeutics Raises USD22 Million in Series A Financing Round 13
Minoryx Therapeutics Raises Additional USD0.8 Million in Seed Financing 15
Minoryx Therapeutics Raises US$2 Million In First Round Of Financing 16
Minoryx Therapeutics Enters Into Licensing Agreement with Universitat de Barcelona and Institut de Investigacio Biomedica de Bellvitge 17
Minoryx Therapeutics Enters into Licensing Agreement with Bellvittge Biomedical 18
University of Barcelona And ICREA Enter Into Licensing Agreement With Minoryx 19
Gain Therapeutics Spin Out from Minoryx Therapeutics 20
Minoryx Therapeutics sl, Key Competitors 21
Minoryx Therapeutics sl, Key Employees 22
List of Figures
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Minoryx Therapeutics sl, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8